We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+38.53%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$524M
AUM Growth
+$84.8M
Cap. Flow
-$21.1M
Cap. Flow %
-4.01%
Top 10 Hldgs %
56.21%
Holding
96
New
14
Increased
18
Reduced
28
Closed
8

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$11.2M
2
DNLI icon
Denali Therapeutics
DNLI
+$8.64M
3
PODD icon
Insulet
PODD
+$8.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.91M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$3.95M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$21M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$16.5M
3
BHVN icon
Biohaven
BHVN
+$7.62M
4
MBX
MBX Biosciences
MBX
+$5.72M
5
KALV
KalVista Pharmaceuticals
KALV
+$5.38M

Sector Composition

Rank Sector Weight
1 Healthcare 92.52%
2 Miscellaneous 7.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNA
51
Atrium Therapeutics
RNA
$233M
$1.72M 0.33%
+128,000
New +$1.67M
ANNX icon
52
Annexon
ANNX
$942M
$1.7M 0.32%
297,812
+180,000
+153% +$995K
CTMX icon
53
CytomX Therapeutics
CTMX
$699M
$1.64M 0.31%
438,407
+208,407
+91% +$796K
RARE icon
54
Ultragenyx Pharmaceutical
RARE
$2.52B
$1.57M 0.3%
47,100
-14,000
-23% -$348K
EPRX
55
Eupraxia Pharmaceuticals
EPRX
$441M
$1.49M 0.28%
+225,600
New +$1.56M
DSGN icon
56
Design Therapeutics
DSGN
$946M
$1.48M 0.28%
+102,600
New +$1.28M
FATE icon
57
Fate Therapeutics
FATE
$291M
$1.42M 0.27%
525,000
-25,000
-5% -$46.3K
MDWD icon
58
MediWound
MDWD
$163M
$1.39M 0.26%
94,405
– –
KURA icon
59
Kura Oncology
KURA
$1.13B
$1.32M 0.25%
120,568
-115,300
-49% -$1.09M
SPRY icon
60
ARS Pharmaceuticals
SPRY
$586M
$1.32M 0.25%
164,285
+25,000
+18% +$215K
MLYS icon
61
Mineralys Therapeutics
MLYS
$2.26B
$1.2M 0.23%
44,490
+6,000
+16% +$165K
IMTX icon
62
Immatics
IMTX
$1.44B
$1.18M 0.23%
116,960
-108,900
-48% -$1.15M
TELA icon
63
TELA Bio
TELA
$31.4M
$1.08M 0.21%
1,441,029
– –
PYPD icon
64
PolyPid
PYPD
$103M
$1.06M 0.2%
207,900
– –
CRBP icon
65
Corbus Pharmaceuticals
CRBP
$211M
$1.01M 0.19%
+107,773
New +$1.02M
INSP icon
66
Inspire Medical Systems
INSP
$1.78B
$812K 0.15%
18,200
– –
ACET icon
67
Adicet Bio
ACET
$84.8M
$811K 0.15%
93,812
– –
SPTX
68
Seaport Therapeutics
SPTX
$1.29B
$704K 0.13%
+32,400
New +$570K
MBX
69
MBX Biosciences
MBX
$3.03B
$652K 0.12%
11,809
-163,656
-93% -$5.72M
BNTX icon
70
BioNTech
BNTX
$25.6B
$651K 0.12%
7,000
– –
ARTV
71
Artiva Biotherapeutics
ARTV
$542M
$651K 0.12%
+67,101
New +$611K
PLRX icon
72
Pliant Therapeutics
PLRX
$68.7M
$555K 0.11%
487,000
– –
SCYX icon
73
SCYNEXIS
SCYX
$53.6M
$553K 0.11%
135,868
-2
-0% -$12
EDIT icon
74
Editas Medicine
EDIT
$485M
$552K 0.11%
+170,470
New +$498K
OBIO icon
75
Orchestra BioMed
OBIO
$312M
$547K 0.1%
126,841
– –
1 2
3
4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, DAFNA Capital Management held 96 positions worth $524M, up 19% from $440M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

DAFNA Capital Management withdrew a net $21.1M in Q2 2026, closing 8 positions and reducing 28 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in NervGen Pharma worth $2.16M.

  • DAFNA Capital Management's largest Q2 2026 buy was NervGen Pharma: 1,050,000 shares worth $2.16M.
  • DAFNA Capital Management added most to Nektar Therapeutics in Q2 2026, an estimated $11.2M increase.
  • DAFNA Capital Management's biggest Q2 2026 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $16.5M.
  • DAFNA Capital Management fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $21M.
  • DAFNA Capital Management's ten largest holdings make up 56% of its $524M portfolio in Q2 2026.
  • DAFNA Capital Management opened 14 new positions and closed 8 in Q2 2026.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $524M.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.